|Year : 2017 | Volume
| Issue : 1 | Page : 34-37
The minimum volume of pleural fluid required to diagnose malignant pleural effusion: A retrospective study
Huimin Wu1, Rahul Khosla2, Prashant K Rohatgi2, Suman S Chauhan3, Edina Paal3, Wen Chen3
1 Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, The George Washington University, Washington, DC 20037, USA
2 Pulmonary and Critical Care Medicine, Veterans Affairs Medical Center, Washington, DC 20422, USA
3 Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center; Department of Pathology, The George Washington University, Washington, DC 20422, USA
|Date of Web Publication||30-Dec-2016|
Pulmonary, Critical Care and Sleep Medicine, The George Washington University, 2150 Pennsylvania Ave NW, Washington, DC 20037
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Pleural fluid cytology is a quick and accurate method to diagnose malignant pleural effusions. The optimal volume of fluid for cytological analysis has not yet been identified, and clinical recommendation based on some published clinical experiences has been to send large volumes of fluid for cytological analysis. A quality improvement initiative at our institution was conducted to determine the volume of fluid sufficient for a diagnosis of malignant pleural effusion. Materials and Methods: The study was approved by the Institutional Review Board. All pleural fluid specimens that were divided into three volumes (25 mL, 50 mL, and 150 mL) and sent for cytological examination were reviewed. Results: A total of 74 samples from 60 individual patients were evaluable. Thirty-six patients (60%) had a previous diagnosis of malignancy. Of the 74 specimens, 26 (35.1%) were positive for malignancy. The detection rate for malignant pleural effusion by cytology for 25 mL, 50 mL, and 150 mL were 88.5%, 96.2%, and 100.0%, respectively (P = 0.16). Two specimens that were negative in the 25 mL samples turned out to be positive in the 50 mL and 150 mL samples. One specimen was negative in the 25 mL and 50 mL samples but positive in the 150 mL sample. Conclusions: Our study did not show any statistically significant difference in the detection of malignant effusion in the 25 mL, 50 mL, and 150 mL group.
Keywords: Cytology, malignant, pleural effusion
|How to cite this article:|
Wu H, Khosla R, Rohatgi PK, Chauhan SS, Paal E, Chen W. The minimum volume of pleural fluid required to diagnose malignant pleural effusion: A retrospective study. Lung India 2017;34:34-7
|How to cite this URL:|
Wu H, Khosla R, Rohatgi PK, Chauhan SS, Paal E, Chen W. The minimum volume of pleural fluid required to diagnose malignant pleural effusion: A retrospective study. Lung India [serial online] 2017 [cited 2019 Dec 13];34:34-7. Available from: http://www.lungindia.com/text.asp?2017/34/1/34/197120
| Introduction|| |
Pleural effusions are common clinical manifestations of benign and malignant diseases. The gold standard to diagnose malignant pleural effusion is to find malignant cells on cytological examination of pleural fluid or histopathology of pleural biopsy. Cytological analysis has sensitivity from 40% to 87% for malignant pleural effusion,,, however, the optimal volume of fluid to be sent for cytological analysis is unclear, and only a few studies have addressed this issue.,,, In an attempt to address this question, we started to divide pleural fluid into three different volumes for cytological examination. We report our findings in this study.
| Materials and Methods|| |
The study was approved by the Institutional Review Board at Washington, DC, Veteran Affair Medical Center. An electronic cytology database was searched for all pleural fluid specimens sent for analysis between April 1, 2009, and July 31, 2015. The inclusion criteria included patients with suspected malignant pleural effusion in whom the pleural fluid was divided into three aliquots of 25 mL, 50 mL, and 150 mL. Patients with pleural effusion which was not suspected to be malignant or was not divided into the above three aliquots were excluded. The search identified 74 specimens which met the above criteria.
All specimens in the current study were processed according to standard clinical laboratory protocols. Specimens were either processed fresh or after refrigeration overnight without fixation. The 25 mL, 50 mL, and 150 mL specimens were transferred into 1, 2, or 3 50 mL centrifuge tubes, respectively. They were centrifuged for 5 min at 2500 revolutions per minutes. For 25 mL and 50 mL specimens, the direct smears and liquid-based preparations (ThinPrep™) were prepared from the sediment. Cell blocks were made from the remaining material. For the 150 mL specimens, direct smears, ThinPrep™ and cell blocks were performed from each of three centrifuge tubes, respectively. The direct smears were stained with Diff-Quik, ThinPrep™ was stained with Papanicolaou stain, and cell blocks were stained with Hematoxylin and Eosin.
Each specimen was categorized as either negative (no malignant cells or atypical cells) or positive (malignant cells). The specific cancer diagnoses were documented. The medical records were then searched, and any previous, or concurrent diagnosis of malignancy was documented. The chest images were reviewed.
The Chi-square tests were done to assess the relationship of demographics, past medical history information, and the malignancy diagnosis. Fisher's exact test was used to confirm the Chi-square tests results for small frequencies.
| Results|| |
There were 74 samples from 60 individual patients, including 58 males and 2 females [Table 1]. The mean age of patients with a positive cytology was 70.6 years (range: 50–91 years, standard deviation [SD] 10.0 years), whereas the mean age of patients with a negative cytology was 69.9 years (range: 42–93 years, SD 11.6 years), P = 0.41. There was no difference in gender, race, and history of smoking between groups with positive or negative pleural fluid cytology. The final diagnosis results are shown in [Table 2].
A total of 36 patients (60%) had a previous diagnosis of malignancy. The primary tumors comprised a heterogeneous group with the most common type being undifferentiated nonsmall cell lung cancer (19.4%), adenocarcinoma of the lung (16.7%), and squamous cell lung cancer (16.7%).
Of the 74 pleural fluid specimens, 26 (35.1%) were positive for malignancy [Table 3]. In seven patients, positive cytology was the first pathologic documentation of malignancy. Effusions in patients with a history of cancer did not have a higher rate of malignant effusions compared to patients without a history of cancer (41.5% vs. 37.9%; P = 0.77) [Table 4].
|Table 4: History of malignancies and the results of the pleural effusion|
Click here to view
The cancer cell type with positive pleural fluid cytology in our study population is shown in [Table 5]. Lung adenocarcinoma was the most common cancer cell type and was diagnosed in 8 of 22 (36.4%) patients.
The results of the size of all the effusions on the chest radiographs before the thoracentesis are shown in [Table 6], which correlate with the volume which was aspirated during the thoracentesis. The chest image findings of patients with malignant pleural effusion on cytology are shown in [Table 7].
|Table 7: Chest radiographic finding of the specimens with malignant pleural effusion on cytology|
Click here to view
The aspirated pleural fluid volumes ranged between 225 mL and 2095 mL with a median volume of 1175 mL. The detection rate for malignant pleural effusion by different volumes is shown in [Table 8]. One specimen with metastatic colon adenocarcinoma and the other with lung adenocarcinoma were negative in the 25 mL samples and positive in the 50 mL and 150 mL samples. One specimen with metastatic colon adenocarcinoma was negative in the 25 mL and 50 mL samples but positive in the 150 mL sample.
| Discussion|| |
Patients with malignant effusion have advanced stage cancer and carry a poor prognosis. Cytological examination of pleural effusion is the most common method to confirm malignant pleural effusion. The diagnostic accuracy of pleural fluid cytology for a malignant effusion ranges from 40% to 87%, which is higher than that of pleural biopsy.,
There are no clear guidelines regarding the minimal volume of fluid needed to diagnose a malignant pleural effusion. Only a few studies have been published regarding the volume required to diagnose malignant pleural effusion. The American College of Physicians Health and Public Policy Committee stated in a position paper that only 50–100 mL of fluid is required for a diagnostic thoracentesis. However, the statement did not specifically address cytological examination for malignancy. The British Thoracic Society recommends that no more than 50 mL is required for adequate assessment. Abouzgheib et al. divided the pleural effusion into first 50 mL and the rest. They found that submission of >50 mL of pleural fluid did not increase diagnostic yield. Swiderek et al. divided the pleural fluid in 10 mL, 60 mL, and ≥150 mL. Based on the study, 60 mL was found to be adequate for diagnosing a malignant pleural effusion. Thomas et al. found 25–50 mL of fluid was adequate to diagnose malignant pleural effusion. The recent retrospective analysis of 2450 cases by Rooper et al. supports the use of 75 mL as a minimum cut-off volume for effusion specimen.
In our study, there was no statistically significant difference in diagnosing malignant pleural effusion amongst the 25 mL, 50 mL, and 150 mL groups. Two specimens were negative in the 25 mL group, but positive in the 50 mL and 150 mL group. One specimen was negative in the 25 mL and 50 mL group, but positive in the 150 mL group.
There was no significant difference in the proportion of positive malignant pleural effusion in patients with a history of malignancy compared to those without a history of malignancy. Malignant effusion was the first presentation of new cancer in seven of our patients.
The mechanism by which pleural effusion develops in a patient with malignancy is one of the determinants for the presence or absence of malignant cells in the fluid. Pleural effusions that form due to the presence of tumor implants on pleural surface or due to direct tumor infiltration of the pleura tend to have malignant cells in the effusion. Pleural effusions can also occur due to the impairment of lymphatic drainage of the pleura either due to tumor infiltration of the lymph nodes or increased resistance to lymph flow into the vascular system. These are called paramalignant effusions  and malignant cells are not present in these effusions.
Another factor could be the histologic type of the underlying tumor which may affect the incidence of positive malignant cells in the pleural effusion. In our study, primary adenocarcinoma of lung and nonlung primarily accounts for 59.1% of the malignant pleural effusions. It could be that these tumors are more likely to have lymphohematogenous invasion with spread to pleural surface.
Although the results from our study and that by Thomas et al. would suggest that 25–50 mL of pleural fluid would be adequate to diagnose malignant pleural effusion and that there were no statistical differences in the diagnostic rate between the three groups in our study, these differences may be clinically relevant. Rooper et al. found that using a volume cut-off of 75 mL is no different from using any greater volume cut-offs, however, definitively benign or malignant effusion cytology results are more likely to come from high-volume specimens above the adequacy threshold of 75 mL. In our opinion, the least amount of volume of pleural fluid that should be processed for cytological examination should be 25 mL and the largest volume that should be submitted should be largest volume that a laboratory can process at one time, without adding significant monetary or time-related cost.
There are several limitations to our study. The sample size and the number of patients with a malignant effusion are small. Majority of the patients in our study were male, and the results may not be applicable in centers with more female patients. We did not evaluate pleural fluid volume larger than 150 mL; hence, we are unable to say if volumes larger than 150 mL add to the diagnostic accuracy of malignant effusions.
| Conclusions|| |
Our study did not show any difference in the detection of malignant effusion in the 25 mL, 50 mL, and 150 mL groups.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
Sallach SM, Sallach JA, Vasquez E, Schultz L, Kvale P. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest 2002;122:1913-7.
Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd
ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143 5 Suppl:e142S-65S.
Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest 2009;135:999-1001.
Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, et al.
Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest 2010;137:68-73.
Thomas SC, Davidson LR, McKean ME. An investigation of adequate volume for the diagnosis of malignancy in pleural fluids. Cytopathology 2011;22:179-83.
Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: A retrospective analysis of 2540 cases. Cancer Cytopathol 2014;122:657-65.
Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:ii4-17.
Sahn SA. Malignant pleural effusions. In: Fishman AP, editor. Fishman's Pulmonary Diseases and Disorders. 4th
ed. The Unitied States: The McGraw-Hill Companies, Inc.; 2008. p. 1505-15.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]